

TABLE OF CONTENTS

• Acknowledgements	III
• Abstract	V
• Table of contents	VII
• List of tables	XV
• List of figures	XXI
• List of abbreviations	XXVII
• List of formulas	XXX

Chapter I: Introduction

1.1. Introduction

1.1.1 Pharmaceutical Analysis	1
1.1.2 Chromatography	3
1.1.3 Mass Spectroscopy	9

1.2. Instrumentation

1.2.1. High performance liquid chromatography (HPLC)	11
1.2.2. Mass Spectrometer	18
1.2.3. Liquid Chromatography-Mass Spectrometry (LC-MS)	19

1.3. Method Development

1.3.1. Analytical Method Development	22
1.3.2. Bio analytical Method Development	23

1.4. Method Validation

1.4.1. Analytical Method Validation	26
1.4.2. Bio analytical Method Validation	37

1.5. References	47
------------------------	-----------

Chapter II: Objectives of the study

2.1. General objectives

2.1.1. Objectives of development and validation of bio analytical methods	51
2.1.2. Objectives of Qualitative and quantitative analysis	52
2.1.3. Objectives of stability indicating assays	52

2.2. Plan of work

2.2.1. Selection of drugs	54
---------------------------	----

Chapter III: Riluzole hydrochloride

3.1. Literature of Riluzole hydrochloride	55
3.2. Profile of the drug	58
3.3. Authentication of drug by spectral studies	61
3.4. Quantitative estimation of Riluzole in human plasma by LC-ESI-MS/MS	
3.4.1. Introduction	63
3.4.2. Experimental	64
3.4.3. Method development	65
3.4.4. Method validation	69
3.4.5. Results and discussion	
3.4.5.1. Method development	105
3.4.5.2. Method validation	107

3.4.6. Summary	109
3.4.7. Conclusion	110
3.5. Development and validation of RP-HPLC method for the determination of Riluzole hydrochloride in bulk and tablet dosage forms	
3.5.1. Introduction	111
3.5.2. Experimental	111
3.5.3. Method development	112
3.5.4. Method validation	116
3.5.5. Results and discussion	
3.5.5.1. Method development	121
3.5.5.2. Method validation	122
3.5.6. Summary	123
3.5.7. Conclusion	124
3.6. An improved stability-indicating HPLC method for Riluzole hydrochloride in bulk and pharmaceutical dosage forms	
3.5.1. Introduction	125
3.5.2. Experimental	125
3.5.3. Method development	126
3.5.4. Method validation	131
3.5.5. Results and discussion	
3.5.5.1. Method development	139
3.5.5.2. Method validation	149
3.5.6. Summary	151
3.5.7. Conclusion	152

3.7. References	153
-----------------	-----

Chapter IV: Rimonabant hydrochloride

4.1. Literature of Rimonabant hydrochloride	156
---	-----

4.2. Profile of the drug	165
--------------------------	-----

4.3. Authentication of drug by spectral studies	168
---	-----

4.4. RP-HPLC method development and validation of Rimonabant hydrochloride in bulk and pharmaceutical dosage forms

4.4.1. Introduction	170
---------------------	-----

4.4.2. Experimental	171
---------------------	-----

4.4.3. Method development	172
---------------------------	-----

4.4.4. Method validation	175
--------------------------	-----

4.4.5. Results and discussion	
-------------------------------	--

4.4.5.1. Method development	183
-----------------------------	-----

4.4.5.2. Method validation	184
----------------------------	-----

4.4.6. Summary	186
----------------	-----

4.4.7. Conclusion	186
-------------------	-----

4.5. A novel validated RP-HPLC method development for the estimation of Rimonabant hydrochloride in bulk and tablet dosage forms

4.5.1. Introduction	187
---------------------	-----

4.5.2. Experimental	187
---------------------	-----

4.5.3. Method development	188
---------------------------	-----

4.5.4. Method validation	191
--------------------------	-----

4.5.5. Results and discussion	
-------------------------------	--

4.5.5.1. Method development	198
4.5.5.2. Method validation	200
4.5.6. Summary	201
4.5.7. Conclusion	202
4.6. A Novel Stability Indicating Liquid Chromatographic Assay for the Estimation of Rimonabant Hydrochloride in Bulk and Pharmaceutical Dosage Forms	
4.6.1. Introduction	203
4.6.2. Experimental	203
4.6.2. Method development	204
4.6.3. Method validation	209
4.6.4. Results and discussion	
4.6.4.1. Method development	214
4.6.4.2. Method validation	222
4.6.5. Summary	223
4.6.6. Conclusion	224
4.7. References	225
Chapter V: Aprepitant	
5.1. Literature of Aprepitant	230
5.2. Profile of the drug	235
5.3. Authentication of drug by spectral studies	238

5.4. A Validated RP-HPLC Method for the Determination of Aprepitant in Bulk and Pharmaceutical Dosage Forms Using Internal Standard

5.4.1. Introduction	240
5.4.2. Experimental	241
5.4.3. Method development	242
5.4.4. Method validation	245
5.4.5. Results and discussion	
5.4.5.1. Method development	252
5.4.5.2. Method validation	254
5.4.6. Summary	256
5.4.7. Conclusion	256

5.5. A Validated Stability Indicating RP-HPLC Method for the Determination of Aprepitant in Bulk and Pharmaceutical Dosage Forms

5.5.1. Introduction	257
5.5.2. Experimental	257
5.5.3. Method development	258
5.5.4. Method validation	262
5.5.5. Results and discussion	
5.5.5.1. Method development	272
5.5.5.2. Method validation	274
5.5.6. Summary	274
5.5.7. Conclusion	275
5.6. References	277

Chapter VI: Orlistat

6.1. Literature of Orlistat	279
6.2. Profile of the drug	282
6.3. Authentication of drug by spectral studies	286
6.4. A new RP-HPLC method development and validation of Orlistat in bulk and pharmaceutical dosage Forms	
6.4.1. Introduction	288
6.4.2. Experimental	288
6.4.3. Method development	289
6.4.4. Method validation	292
6.4.5. Results and discussion	
6.4.5.1. Method development	299
6.4.5.2. Method validation	300
6.4.6. Summary	301
6.4.7. Conclusion	302
6.5. References	303

Chapter VII: Ropinirole hydrochloride

7.1. Literature of Ropinirole hydrochloride	304
7.2. Profile of the drug	307
7.3. Authentication of drug	311

7.4. RP-HPLC method development and validation of Ropinirole hydrochloride in bulk and pharmaceutical dosage forms

7.4.1. Introduction	313
7.4.2. Experimental	313
7.4.3. Method development	315
7.4.4. Method validation	317
7.4.5. Results and discussion	
7.4.5.1. Method development	325
7.4.5.2. Method validation	327
7.4.6. Summary	328
7.4.7. Conclusion	328
7.5. References	329
Appendix: Research publications in journals	330